Novocure Limited (NVCR)
|Net Income (ttm)||19.15M|
|Trading Day||January 22|
|Day's Range||167.83 - 172.95|
|52-Week Range||57.05 - 178.94|
A new paradigm in cancer treatment is developing
Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy.
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.
After a stellar 3x rise since the March 23 levels of this year, at the current price of around $170 per share we believe Novocure stock, a company working on an innovative cancer treatment alt...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021.
Why Novocure, Leading Medical Devices Stock, Is One To Watch In 2021
Novocure is a medical devices company launched in 2000 to test a theory put forth by Yoram Palti, a professor of physiology and biophysics. Novocure that thinks of themselves as "sort of a hyb...
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced national reimbursement in Switzerland for Optune in combination with temozolomide for the treatment of newly diagnosed GBM.
First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced the first patient has been enrolled in its global phase 3 TRIDENT trial.
Stock Market Analysis: Can Bulls Keep Running After A Big Week? Novocure, Intuitive Surgical Strong
Stock market analysis: Can bulls keep running after another big week? Novocure, Intuitive Surgical strong.
Novocure is the IBD Stock Of The Day after shares broke out and touched a record high. Investor enthusiasm is frothing NVCR stock with several important studies due in 2021.
Dow At New High: Google, PayPal Flash Buy Signals; Novocure Tumbles
Dow Jones hits record high: Google, PayPal flash buy signals; Novocure tumbles. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, inv...
The most likely culprit: profit-taking.
Rebounds from the 10-week line and breaking trend lines offer ways to start early positions in leaders. AMD, Twilio and Novocure offer both buy signals now.
Stock market analysis; Novocure Flashes Several Buy Signals, Qorvo Sets Up New Entry
Stock market analysis; Novocure flashes several buy signals, Qorvo sets up new entry. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock list...
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.
These stocks might not get much attention, but they deserve yours.
Novocuore has disruptive technologies in cancer treatments. The company has enormous room for growth if management delivers.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure has received the CE mark for the NovoTTF-100L system, enabling commercialization of the device to treat MPM in the E.U. and Switzerland.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure's Research and Development Day will review two decades of Tumor Treating Fields research and introduce exciting new directions.
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced the closing of a new $150 million revolving credit facility with a syndicate of relationship banks.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced the closing of $575 million 0% convertible senior notes private placement.
Novocure saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before. The post Growing Novocure Sees Composite Rating Improve To 96 appeared first on Investor's Bu...
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure prices $500 million 0% convertible senior notes through a private placement.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”).
Novocure Ltd (NVCR) CEO Asaf Danziger on Q3 2020 Results - Earnings Call Transcript
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the quarter ended September 30, 2020, and provided a company update.
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced it has entered into a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology.
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.
Is (NVCR) Outperforming Other Medical Stocks This Year?
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open.
ST. HELIER, Jersey--(BUSINESS WIRE)--The event on Nov. 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research.
Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma ...
Indexes Fade Strong Gains; Novocure, Brinker Hold Up
The Nasdaq held a modest gain in afternoon trading Wednesday after rising 1.6% intraday.
The IBD SmartSelect Composite Rating for Novocure increased from 94 to 96 Thursday. The post Top-Rated Stocks: Novocure Sees Composite Rating Climb To 96 appeared first on Investor's Business...
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020.
Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise
Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020.
NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2020 Results - Earnings Call Transcript
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update.
Have you missed out on the rally of these 5 stocks in the past three years? LivePerson, Novocure, Splunk, RingCentral and Teladoc?
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program.
The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person con...
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
ST. HELIER, Jersey--(BUSINESS WIRE)--The first patient has been enrolled in Novocure's EF-33 phase 2 pilot trial of Tumor Treating Fields delivered using high-intensity arrays.
This disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016.
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
ST. HELIER, Jersey--(BUSINESS WIRE)-- #LCSM--Novocure has entered into a clinical trial collaboration agreement with MSD to develop Tumor Treating Fields together with KEYTRUDA® for NSCLC.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its product... [Read more...]
Medical Instruments & Supplies
|IPO Date |
Oct 2, 2015
|Stock Exchange |
|Ticker Symbol |
In 2019, Novocure's revenue was $351.32 million, an increase of 41.62% compared to the previous year's $248.07 million. Losses were -$7.23 million, -88.62% less than in 2018.
According to 9 analysts, the average rating for Novocure stock is "Hold." The 12-month stock price forecast is 136.00, which is a decrease of -19.57% from the latest price.